Hiroki Hosoi

Dr. Hiroki Hosoi

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2021 in Journal of Autoimmunity
Verified
Journal Article
Closed access
STShotaro Tabata
Shotaro Tabata
HHHiroki Hosoi
Hiroki Hosoi
SMShogo Murata
Shogo Murata
STSatomi Takeda
Satomi Takeda
TMToshiki Mushino
Toshiki Mushino
TSTakashi Sonoki
Takashi Sonoki

Verified
Journal Article
Open access
PDF file
YYYusuke Yamashita
Yusuke Yamashita
SMShuhei Morita
Shuhei Morita
HHHiroki Hosoi
Hiroki Hosoi
HKHiroshi Kobata
Hiroshi Kobata
SKShohei Kishimoto
Shohei Kishimoto
STShinobu Tamura
Shinobu Tamura
Background: Inositol-requiring enzyme 1α (IRE1α), along with protein kinase R-like endoplasmic reticulum kinase (PERK), is a principal regulator of the unfolded protein response (UPR). Recently, the ‘mono’-specific IRE1α inhibitor, kinase-inhibiting RNase attenuator 6 (KIRA6), demonstrated a promising effect against multiple myeloma (MM). Side-stepping the clinical translation, a detailed UPR phenotype in patients with MM and the mechanisms of how KIRA8 works in MM remains unclear. Methods: We characterized UPR phenotypes in the bone marrow of patients with newly diagnosed MM. Then, in human MM cells we analyzed the possible anti-tumor mechanisms of KIRA8 and a Food and Drug Administration (FDA)-approved drug, nilotinib, which we recently identified as having a strong inhibitory effect against IRE1α activity. Finally, we performed an RNA-sequence analysis to detect key IRE1α-related molecules against MM. Results: We illustrated the dominant induction of adaptive UPR markers under IRE1α over the PERK pathway in patients with MM. In human MM cells, KIRA8 decreased cell viability and induced apoptosis, along with the induction of C/EBP homologous protein (CHOP); its combination with bortezomib exhibited more anti-myeloma effects than KIRA8 alone. Nilotinib exerted a similar effect compared with KIRA8. RNA-sequencing identified Polo-like kinase 2 (PLK2) as a KIRA8-suppressed gene. Specifically, the IRE1α overexpression induced PLK2 expression, which was decreased by KIRA8. KIRA8 and PLK2 inhibition exerted anti-myeloma effects with apoptosis induction and the regulation of cell proliferation. Finally, PLK2 was pathologically confirmed to be highly expressed in patients with MM. Conclusion: Dominant activation of adaptive IRE1α was established in patients with MM. Both KIRA8 and nilotinib exhibited anti-myeloma effects, which were enhanced by bortezomib. Adaptive IRE1α signaling and PLK2 could be potential therapeutic targets and biomarkers in MM.

20 September 2022 in Journal of Autoimmunity
Verified
Journal Article
Closed access
HHHiroki Hosoi
Hiroki Hosoi
MTMisato Tane
Misato Tane
HKHideki Kosako
Hideki Kosako
MIMasaki Ibe
Masaki Ibe
MTMasahiro Takeyama
Masahiro Takeyama
TSTakashi Sonoki
Takashi Sonoki

16 May 2022 in Thrombosis Journal
Verified
Journal Article
Open access
PDF file
HHHiroki Hosoi
Hiroki Hosoi
YAYuina Akagi
Yuina Akagi
TMToshiki Mushino
Toshiki Mushino
MTMasahiro Takeyama
Masahiro Takeyama
NMNaoto Minoura
Naoto Minoura
TSTakashi Sonoki
Takashi Sonoki
Background: Acquired hemophilia A (AHA) is a rare autoimmune disease characterized by bleeding events. Recombinant activated factor VII (rFVIIa) is a first-line bypassing agent, which is effective against clinically significant bleeding. However, there is no standard way of tapering and discontinuing rFVIIa, mainly because there is no established method for monitoring rFVIIa therapy for AHA. Case presentation: Here, we report three AHA cases, in which we adjusted the rFVIIa dosing interval based on the results of thromboelastography (TEG) performed just before the administration of the next dose of rFVIIa. The dosing interval of rFVIIa was prolonged based on the reaction rate time (R) according to TEG, which is correlated with coagulation factor activity. The R-value reference range reported by the manufacturer of the TEG system was used as a threshold for making decisions. In these three cases, there was no rebleeding, and the patients’ ability to perform activities of daily living did not decline. Conclusion: Our cases suggest that conducting TEG-based monitoring just before the administration of the next dose of rFVIIa may be useful for guiding increases in the rFVIIa dosing interval without causing rebleeding events. Further investigations are warranted to examine how TEG could be used to determine the most appropriate rFVIIa dosing interval, e.g., through regular TEG-based monitoring, and the optimal TEG-derived threshold for indicating changes to the rFVIIa dosing interval.

31 March 2023 in International Journal of Hematology
Verified
Journal Article
Open access
PDF file
MTMisato Tane
Misato Tane
HKHideki Kosako
Hideki Kosako
HHHiroki Hosoi
Hiroki Hosoi
KTKayoko Tabata
Kayoko Tabata
THTakayuki Hiroi
Takayuki Hiroi
TSTakashi Sonoki
Takashi Sonoki
TAFRO syndrome is a rare systemic inflammatory disease. Its pathogenesis mainly involves excessive cytokine secretion and autoimmune dysfunction. Although its etiology is unclear, some viral infections have been reported to cause it. Here, we report a case of severe systemic inflammation mimicking TAFRO syndrome that arose after COVID-19. A 61-years-old woman suffered from a continuous fever, ascites, and edema after contracting COVID-19. She developed progressive thrombocytopenia, renal failure, and elevated C-reactive protein levels. She was tentatively diagnosed with multisystem inflammatory syndrome in adults (MIS-A) and received steroid pulse therapy. However, she exhibited worsening fluid retention and progressive renal failure, which are not typical of MIS-A. A bone marrow examination showed reticulin myelofibrosis and an increased number of megakaryocytes. Although a definitive diagnosis of TAFRO syndrome was not made according to current diagnostic criteria, we determined that her symptoms were clinically consistent with those of TAFRO syndrome. Combination therapy, including steroid pulse therapy, plasma exchange, rituximab, and cyclosporine, improved her symptoms. There are pathological similarities between hyperinflammation that arises after COVID-19 and TAFRO syndrome in terms of the associated cytokine storms. COVID-19 may have triggered the development of systemic inflammation mimicking TAFRO syndrome in this case.

1 November 2022 in Journal of Geriatric Oncology
Verified
Journal Article
Closed access
THTakayuki Hiroi
Takayuki Hiroi
HHHiroki Hosoi
Hiroki Hosoi
KKKodai Kuriyama
Kodai Kuriyama
SMShogo Murata
Shogo Murata
MMMasaya Morimoto
Masaya Morimoto
TSTakashi Sonoki
Takashi Sonoki